Axonal degeneration is a fundamental pathological process shared across neurodegenerative diseases, yet the specific mechanisms, triggers, and clinical manifestations differ significantly between conditions. This comparison page examines how axonal degeneration manifests in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).
Unlike neuronal cell body death, axonal degeneration often occurs as an early, independent event—making it a critical therapeutic target for preserving neuronal connectivity and function before irreversible damage occurs.
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---|---|---|---|---|---|
| Primary Axonal Abnormality | Distal axonopathy, tau-mediated transport disruption | Dopaminergic axon loss in substantia nigra | Motor neuron axon degeneration | Frontotemporal network axonal dysfunction | Striatal medium spiny neuron axon degeneration |
| Key Trigger | Amyloid-beta, tau hyperphosphorylation | Alpha-synuclein aggregation, mitochondrial dysfunction | TDP-43/SOD1 aggregation, excitotoxicity | TDP-43, progranulin, tau | Mutant huntingtin, transcriptional dysregulation |
| Affected Tracts | Corticocortical, hippocampal connections | Nigrostriatal, autonomic fibers | Corticospinal, peripheral nerves | Frontotemporal connections, U-fibers | Striatocortical, corticostriatal |
| SARM1 Involvement | Moderate (energy failure) | High (PINK1/Parkin pathway) | High (energy crisis) | Moderate | High (metabolic dysfunction) |
| Transport Defect | Kinesin dysfunction, microtubule disruption | Dynein dysfunction, mitochondrial transport | Kinesin/dynein impairment | Variable by subtype | Motor protein dysfunction |
| Myelin Involvement | Secondary demyelination | Secondary demyelination | Primary and secondary | Variable | Secondary |
| Clinical Correlation | Early cognitive decline | Motor symptoms, autonomic dysfunction | Weakness, spasticity | Behavior/language changes | Chorea, cognitive decline |
In Alzheimer's disease, axonal degeneration occurs early and progresses throughout the disease course. Key mechanisms include:
Tau-Mediated Transport Disruption
Pathological tau hyperphosphorylation disrupts microtubule stability, impairing axonal transport of organelles, vesicles, and signaling molecules. Tau accumulation in axons correlates with cognitive decline and precedes neurofibrillary tangle formation in vulnerable brain regions [1].
Amyloid-Beta Toxicity
Aβ oligomers directly impair axonal transport through:
Axonal Initial Segment (AIS) Damage
The AIS shows early tau pathology in AD, disrupting action potential initiation and axonal polarity. AIS breakdown contributes to network dysfunction before significant neuronal loss [2].
Therapeutic Implications: Strategies targeting tau pathology, microtubule stabilization, and axonal protection (e.g., SARM1 inhibitors) are actively being investigated [3].
Parkinson's disease features prominent axonal degeneration, particularly in dopaminergic neurons:
Dopaminergic Axon Vulnerability
The long, unmyelinated axons of substantia nigra pars compacta neurons are particularly vulnerable due to:
Alpha-Synuclein Pathology
Lewy neurites (abnormal axonal inclusions) represent early axonal pathology:
PINK1/Parkin Pathway
Mutations in PINK1 and PARKIN impair mitophagy, leading to accumulation of dysfunctional mitochondria in axons. This energy crisis triggers SARM1-mediated axonal degeneration [4].
Axonal Spheroids
PD brains show widespread axonal spheroids—beaded, swollen axons indicating transport breakdown. These precede Lewy bodies and neuronal loss.
ALS features aggressive axonal degeneration of motor neurons:
TDP-43 Pathology
TDP-43 aggregates in motor neuron axons disrupt:
SOD1 Mutations
Mutant SOD1 causes:
Excitotoxicity
Excessive glutamate signaling leads to:
Corticospinal Tract Degeneration
Upper motor neuron axons show early degeneration with:
FTD shows heterogeneous axonal involvement depending on the subtype:
TDP-43 Pathological Subtypes
Progranulin Deficiency
Progranulin haploinsufficiency leads to:
Tau Pathology (CBD/PSP)
Tauopathies within the FTD spectrum show:
Frontotemporal Networks
Axonal degeneration in FTD targets:
Huntington's disease features early axonal pathology in striatal and cortical neurons:
Mutant Huntingtin Effects
mHTT disrupts:
Striatal Medium Spiny Neuron (MSN) Axons
These neurons show:
Cortical Axonal Pathology
Cortical neurons show:
Energy Metabolism
mHTT impairs:
All five diseases share several common axonal degeneration pathways:
The SARM1 pathway is a universal executor of axonal death across neurodegenerative conditions:
Mitochondrial impairment is universal:
All diseases show transport defects:
Calcium homeostasis disruption:
| Target | Approach | Disease Relevance | Status |
|---|---|---|---|
| SARM1 Inhibitors | NAD+ preservation | All diseases | Pre-clinical/Phase 1 |
| Microtubule Stabilizers | Transport restoration | AD, FTD | Clinical trials |
| Mitochondrial Protectants | Energy preservation | PD, ALS, HD | Clinical trials |
| Calcium Channel Blockers | Calpain inhibition | AD, ALS | Pre-clinical |
| Kinesin Modulators | Transport enhancement | AD, PD | Pre-clinical |
| TDP-43 Aggregation Inhibitors | RNA transport | ALS, FTD | Pre-clinical |
| NMNAT2 Enhancers | Axonal NAD+ support | All diseases | Pre-clinical |
| NCT ID | Target | Disease | Phase | Status |
|---|---|---|---|---|
| NCT05633490 | SARM1 inhibitor | ALS | Phase 1 | Recruiting |
| NCT05318985 | Sodium phenylbutyrate/taurursodiol | ALS | Phase 3 | Completed |
| NCT04831814 | Edaravone | ALS | Phase 3 | Completed |
| NCT04260360 | CoQ10 | PD | Phase 2 | Completed |
| NCT03710156 | Inosine | PD | Phase 2 | Completed |
| NCT03062418 | Pioglitazone | AD | Phase 2 | Completed |
| NCT01767311 | Lecanemab | AD | Phase 3 | Completed |
| Gene | Function | Disease Association |
|---|---|---|
| KIF5A | Kinesin heavy chain | ALS, HSP |
| KIF1A | Anterograde transport | Hereditary spastic paraplegia |
| DCTN1 | Dynactin subunit | ALS, PD |
| SPG11 | Spastizin | Hereditary spastic paraplegia |
| SPAST | Spastin | Hereditary spastic paraplegia |
| Gene | Function | Disease Association |
|---|---|---|
| NMNAT2 | NAD+ synthesis | Axonal maintenance |
| SARM1 | NADase | Axonal degeneration execution |
| WLDs | NMNAT1-UCHL1 fusion | Axonal protection (mouse) |
| ATL3 | Atlastin | Hereditary neuropathy |
| Gene | Disease | Role |
|---|---|---|
| MAPT | AD, FTD | Tau pathology, transport disruption |
| SNCA | PD | Lewy neurite formation |
| TARDBP | ALS, FTD | RNA transport dysfunction |
| SOD1 | ALS | Mitochondrial dysfunction |
| HTT | HD | Transcriptional dysregulation |
| GRN | FTD | Lysosomal dysfunction |
| Biomarker | Disease | Source | Significance |
|---|---|---|---|
| Neurofilament light (NfL) | ALS, PD, AD | CSF, blood | Axonal damage marker |
| phosphorylated tau (p-tau) | AD | CSF | Axonal tau pathology |
| α-Synuclein PTMs | PD | CSF | Axonal Lewy pathology |
| TDP-43 fragments | ALS, FTD | CSF | Axonal TDP-43 pathology |
Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease. 2002. ↩︎
Axon initial segment organization and dysfunction in neurological disease. Nature Reviews Neurology. 2022. ↩︎
Mechanisms of axonal degeneration. Nature Reviews Neuroscience. 2023. ↩︎
SARM1 and the innate immune response to axonal injury. Trends in Neurosciences. 2022. ↩︎
SARM1 and the molecular mechanism of axonal degeneration. 2020. ↩︎